Technical Analysis for AMPE - Ampio Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 0.5172 3.44% 0.02
AMPE closed up 3.44 percent on Friday, September 20, 2019, on 73 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical AMPE trend table...

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish 0.00%
Crossed Above 20 DMA Bullish 3.44%
200 DMA Resistance Bearish 5.55%
Fell Below 20 DMA Bearish 5.55%
Inside Day Range Contraction 5.55%
200 DMA Resistance Bearish 5.55%
20 DMA Support Bullish 5.55%
200 DMA Resistance Bearish 2.21%
20 DMA Support Bullish 2.21%
1,2,3 Pullback Bullish Bullish Swing Setup 2.21%

Older signals for AMPE ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, engages in the discovery and development of pharmaceutical drugs and diagnostic products to identify, treat, and prevent metabolic disorders, eye diseases, kidney diseases, acute and chronic inflammation diseases, and male sexual dysfunction. Its products include Ampion, a non-steroidal anti-inflammatory biologic to treat inflammatory conditions and autoimmune diseases; Optina, an orally administered danazol for the treatment of diabetic macular edema; Vasaloc for the treatment of diabetic nephropathy; and Zertane, an oral drug for treating male sexual dysfunction to premature ejaculation, which is under Phase III clinical trial. The company is also developing a handheld oxidation-reduction potential diagnostic device for use at home or in healthcare facilities that will measure the oxidants/antioxidant balances in human blood and plasma; and methylphenidate derivatives for cancer, which are in pre-clinical development. Ampio Pharmaceuticals, Inc. is headquartered in Greenwood Village, Colorado.
Health Biopharmaceutical Cancer Life Sciences Diabetes Autoimmune Diseases Healthcare Facilities Diagnostic Products Kidney Diseases Diabetic Nephropathy Macular Edema Diabetic Retinopathy Kidney Disease Metabolic Disorders Diabetic Macular Edema Eye Diseases
Is AMPE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.31
52 Week Low 0.36
Average Volume 733,168
200-Day Moving Average 0.5101
50-Day Moving Average 0.4419
20-Day Moving Average 0.4969
10-Day Moving Average 0.5019
Average True Range 0.0301
ADX 34.44
+DI 26.9377
-DI 13.029
Chandelier Exit (Long, 3 ATRs ) 0.4625
Chandelier Exit (Short, 3 ATRs ) 0.5003
Upper Bollinger Band 0.5323
Lower Bollinger Band 0.4615
Percent B (%b) 0.79
BandWidth 14.24834
MACD Line 0.0173
MACD Signal Line 0.0193
MACD Histogram -0.002
Fundamentals Value
Market Cap 35.29 Million
Num Shares 68.2 Million
EPS -0.21
Price-to-Earnings (P/E) Ratio -2.46
Price-to-Sales 0.00
Price-to-Book 19.82
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.54
Resistance 3 (R3) 0.54 0.53 0.54
Resistance 2 (R2) 0.53 0.52 0.53 0.54
Resistance 1 (R1) 0.52 0.52 0.53 0.53 0.54
Pivot Point 0.51 0.51 0.51 0.51 0.51
Support 1 (S1) 0.51 0.50 0.51 0.51 0.50
Support 2 (S2) 0.49 0.50 0.50 0.50
Support 3 (S3) 0.49 0.49 0.50
Support 4 (S4) 0.49